Skip to main content

5 Result(s)

within Xuanye Zhang Remove this filter Cancer Research Remove this filter

and

  1. No Access

    Article

    Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer

    The rise of immune checkpoint inhibitors (ICIs) in recent years has coincided with unusual clinical response patterns. Modification of the sum of longest diameters (SLD)-based threshold that reflecting dynamic...

    Wei Du, Chen Chen, Lin-feng Luo, Li-na He… in Journal of Cancer Research and Clinical On… (2023)

  2. Article

    Correction to: Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus

    Zuan Lin, Xuanye Zhang, Yixin Zhou, Chen Chen, Li-na He… in Cancer Immunology, Immunotherapy (2022)

    Download PDF (292 KB) View Article

  3. No Access

    Article

    Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus

    The use of anti-programmed cell death-1 (PD-1) antibodies in treating malignancies is increasing; however, most registered clinical trials on anti-PD-1 antibodies exclude patients infected with hepatitis B virus ...

    Zuan Lin, Xuanye Zhang, Yixin Zhou, Chen Chen, Li-na He… in Cancer Immunology, Immunotherapy (2022)

  4. No Access

    Article

    Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

    Programmed cell death-ligand 1 inhibitors plus chemotherapy (PD-L1 + Chemo) have achieved substantial progress in extensive-stage small-cell lung cancer (ES-SCLC). However, evidence about programmed cell death...

    Hui Yu, ** Chen, **uyu Cai, Chen Chen, Xuanye Zhang… in Cancer Immunology, Immunotherapy (2022)

  5. Article

    Open Access

    Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma

    Advanced natural killer/T cell lymphoma (NKTL) has demonstrated poor prognosis with currently available therapies. Here, we report the efficacy of anti-programmed death 1 (PD-1) antibody with the P-GEMOX (pega...

    Jun Cai, Panpan Liu, Huiqiang Huang, Yajun Li… in Signal Transduction and Targeted Therapy (2020)

    Download PDF (2785 KB) View Article